Trial Profile
Clinical Trials Insight: 700057341
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Jul 2010
Price :
$35
*
At a glance
- Drugs B7-2 GM-CSF cancer gene therapy (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Radient Pharmaceuticals Corporation
- 24 Jun 2010 Results have been reported in a Radient Pharmaceuticals media release.
- 24 Jun 2010 New trial record